Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track CORT with free AI briefings, catalyst countdowns, and dilution alerts.

CORT — CORCEPT THERAPEUTICS INC

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$108.7M Cash on Hand

CF+ Cash Runway

10.6% Short Interest

💊 Upcoming FDA Decisions

PDUFA Date	Drug	Indication	Type	PoA
2026-07-11	—	Platinum-Resistant Ovarian Cancer <P STYLE="margin-	NDA	81%

PoA = estimated probability of approval from published base rates and live data. See the full PDUFA calendar →

🧪 Upcoming Trial Catalysts

2026-08-01 · Phase 2 — Recruiting — Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecologic
2026-09-01 · Phase 2 — Active Trial — A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepati
2026-09-01 · Phase 1, Phase 2 — Recruiting — Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Mal
2026-09-01 · Phase 2 — Recruiting — Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
2026-10-01 · Phase 2 — Recruiting — Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
2026-10-30 · Phase 1 — Recruiting — Evaluating the Pharmacokinetics and Safety of Miricorilant

📊 Drug Pipeline

Drug	Indication	Phase	Status
Mifepristone 300 MG [Korlym]	Hypercortisolism	PHASE4	COMPLETED
Relacorilant, 100 mg and 25 mg	Metastatic Pancreatic Ductal Adenocarcinoma	PHASE3	TERMINATED
Relacorilant 150 mg once daily (QD)	Ovarian Neoplasm	PHASE3	ACTIVE_NOT_RECRUITING
Nab-paclitaxel 80 mg/m^2	Ovarian Neoplasm	PHASE3	ACTIVE_NOT_RECRUITING
Nab-paclitaxel 100 mg/m^2	Ovarian Neoplasm	PHASE3	ACTIVE_NOT_RECRUITING
Nab-paclitaxel	Metastatic Pancreatic Ductal Adenocarcinoma	PHASE3	TERMINATED
Miricorlilant	Antipsychotic-induced Weight Gain (AIWG)	PHASE2	COMPLETED
Gemcitabine	Adenocarcinoma	PHASE2	RECRUITING
Gemcitabine 1000 mg/m^2	Adenocarcinoma	PHASE2	RECRUITING
Mifepristone	Metastatic Breast Cancer	PHASE2	RECRUITING

💰 Cash Runway & Dilution Risk

CORT holds $108.7M in cash and its operations are currently cash-flow neutral or positive. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for CORT free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-06-04	Guyer William	Purchase	$519,275
2026-06-04	Guyer William	Sale	$281,341
2026-06-04	Guyer William	Sale	$0
2026-06-03	Mokari Atabak	Purchase	$1.1M
2026-06-03	Mokari Atabak	Purchase	$0

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2025-12-30	—	NDA	+0%	-12.1%	-55.2%

Browse all historical PDUFA outcomes →

Get the full CORT picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for CORT and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z